EGFR and cancer: From the drug sensitivity data, the cancer drugs targeting kinases (Dasatinib, Bosutinib, Axitinib, Alectinib), PI3K/MTOR pathway (Idelalisib, Temsirolimus), MEK pathway (Trametinib, Dabrafenib), EGFR signaling (Cetuximab, Gefitinib), proteasome (Bortezomib), HDACs (Vorinostat, Belinostat), cell cycle (Paclitaxel, Docetaxel, Palbociclib), Retinoid receptors (Bexarotene) were found to be sensitive to mutations in genes from multiple DDR clusters.